Abstract
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.
| Original language | English |
|---|---|
| Publisher | S. Karger AG |
| Number of pages | 144 |
| ISBN (Print) | 9783805595308, 9783805595292 |
| DOIs | |
| Publication status | Published - Aug 13 2010 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Anti-VEGF. / Bandello, Francesco; Parodi, M. Battaglia; Augustin, A. J.; Iacono, P.; Schlingemann, R. O.; Schmidt-Erfurth, U.; Verbraak, F. D.
S. Karger AG, 2010. 144 p.Research output: Book/Report › Book
}
TY - BOOK
T1 - Anti-VEGF
AU - Bandello, Francesco
AU - Parodi, M. Battaglia
AU - Augustin, A. J.
AU - Iacono, P.
AU - Schlingemann, R. O.
AU - Schmidt-Erfurth, U.
AU - Verbraak, F. D.
PY - 2010/8/13
Y1 - 2010/8/13
N2 - The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.
AB - The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.
UR - http://www.scopus.com/inward/record.url?scp=84925957027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925957027&partnerID=8YFLogxK
U2 - 10.1159/isbn.978-3-8055-9530-8
DO - 10.1159/isbn.978-3-8055-9530-8
M3 - Book
AN - SCOPUS:84925957027
SN - 9783805595308
SN - 9783805595292
BT - Anti-VEGF
PB - S. Karger AG
ER -